Cited by 142Hepatitis C virus researchTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C

Open access

RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., MILLER, A. H.·2007·Alimentary Pharmacology & Therapeutics

DOI 10.1111/j.1365-2036.2007.03316.x

Open this paper in CoChat — free account Open PDF

Abstract

SUMMARY: Background Whether antidepressants prevent depression during interferon‐alpha/ribavirin treatment for hepatitis C virus infection has yet to be established. Aim To investigate the use of paroxetine in a prospective, double‐blind, placebo‐controlled study for this indication. Methods Sixty‐one hepatitis C virus‐infected patients were randomly assigned to the antidepressant, paroxetine (n = 28), or placebo (n = 33), begun 2 weeks before and continued for 24 weeks during interferon‐alpha/ribavirin treatment. Primary endpoints included development of major depression and severity of depressive symptoms measured by the Montgomery Asberg Depression Rating Scale (MADRS). Results Rates of major depression during the study were low (17%) and did not differ between groups. Nevertheless, using published MADRS cut‐off scores, the percent of subjects who met criteria for mild, moderate or severe depression during interferon‐alpha/ribavirin therapy was significantly lower in paroxetine‐ vs. placebo‐treated subjects (P = 0.02, Fisher’s exact test). Assignment to paroxetine was also associated with significantly reduced depressive symptom severity. This effect was largely accounted for by participants with depression scores above the median (MADRS > 3) at baseline in whom paroxetine was associated with a maximal reduction in MADRS scores of 10.3 (95% CI: 2.1–18.5) compared with placebo at 20 weeks (P < 0.01). Study limitations included a small sample size and high drop‐out rate. Conclusion This double‐blind, placebo‐controlled trial provides preliminary data in support of antidepressant pre‐treatment in hepatitis C virus patients with elevated depressive symptoms at baseline.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2007.03316.x

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Moisés Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,386
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Handbook of Psychiatric Measures
Salzman, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,172
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Self-citation
Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
McHutchison, J. G., Manns, M. P., Patel, K., Poynard, T., Lindsay, K. L., TREPO, C. G., Dienstag, J. L., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. K. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819

Show all 60 references

Research works printed but not linked: 3

10.1176/appi.ps.57.4.570 · DOI
Anonymous, 2005, Physicians’ Desk Reference
Jacobson IM, 2005, Weight‐based ribavirin (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN‐R study, a US community based trial, Hepatol, 1, 749A

Sorted by citations

PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citation
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Self-citation
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Shui, L., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 852
Altered Expression of Genes Involved in Inflammation and Apoptosis in Frontal Cortex in Major Depression
Shelton, R. C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D. A., & Mirnics, K. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.52 · Cited by 511
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460
Tryptophan Metabolism in Depression: A Narrative Review with a Focus on Serotonin and Kynurenine Pathways
Correia, A. S., & Vale, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158493 · Cited by 392
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder
Anisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292
Cumulative Depression Episodes Predict Later C-Reactive Protein Levels: A Prospective Analysis
Copeland, W. E., Shanahan, L., Worthman, C., Angold, A., & Costello, E. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.023 · Cited by 265
Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface
Miller, A. H. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.08.006 · Cited by 261
Self-citation
Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression
Shelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 264
Self-citation
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253
Self-citation
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial
Su, K.-P., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Chang, J. P.-C., Chang, H.-C., & Pariante, C. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.008 · Cited by 205
Depression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
The biology of depression in cancer and the relationship between depression and cancer progression
Sotelo, J. L., Musselman, D. L., & Nemeroff, C. B. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.875891 · Cited by 188
Inflammation, Sanitation, and Consternation: Loss of Contact With Coevolved, Tolerogenic Microorganisms and the Pathophysiology and Treatment of Major Depression
Raison, C. L., Lowry, C. A., & Rook, G. A. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.161 · Cited by 169
Self-citation
Maladaptive and adaptive emotion regulation through music: a behavioral and neuroimaging study of males and females
Carlson, E. J., Saarikallio, S. H., Toiviainen, P., Bogert, B., Kliuchko, M., & Brattico, E. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00466 · Cited by 192
Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021 / 012
Sarrazin, C., Berg, T., Roß, R. S., Schirmacher, P., Wedemeyer, H. H., Neumann, U. P., Schmidt, H., Spengler, U., Wirth, S., Kessler, H. H., et al. (2010) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0028-1110008 · Cited by 166
Inflammation in depression: is adiposity a cause?
Shelton, R. C., & Miller, A. H. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/rshelton · Cited by 143
Self-citation
Minocycline treatment ameliorates interferon-alpha- induced neurogenic defects and depression-like behaviors in mice
Zheng, L., Kaneko, N., & Sawamoto, K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00005 · Cited by 127
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study
Kraus, M. R., Schäfer, A., Schöttker, K., Keicher, C., Weißbrich, B., Hofbauer, I., & Scheurlen, M. (2007) · Gut · doi:10.1136/gut.2007.131607 · Cited by 118
Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation
Hoyo-Becerra, C., Schlaak, J., & Hermann, D. M. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.06.200 · Cited by 120
Citalopram reduces endotoxin-induced fatigue
Hannestad, J., DellaGioia, N., Ortiz, N., Pittman, B., & Bhagwagar, Z. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.013 · Cited by 95
Role of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment
Raison, C. L., & Miller, A. H. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343966 · Cited by 88
Self-citation
Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Self-citation
A cross-sectional study of functional disabilities and perceived cognitive dysfunction in patients with major depressive disorder in South Korea: The PERFORM-K study
Kim, J. M., Chalem, Y., di Nicola, S., Hong, J. P., Won, S. H., & Milea, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.022 · Cited by 86
Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update
Sockalingam, S., Links, P. S., & Abbey, S. E. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01393.x · Cited by 79
De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C
Martín‐Santos, R., Díez, C., Castellví, P., Navinés, R., Miquel, M., Masnou, H., Soler, A., Ardévol, M., GARCÍA, F., Galeras, J. A., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03568.x · Cited by 80
The Role of Inflammation in the Pathophysiology of Depression: Different Treatments and Their Effects
Lotrich, F. E., El-Gabalawy, H. S., Guenther, L., & Ware, C. F. (2011) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.110903 · Cited by 76
“WHAT'S BUGGING THE GUT IN OCD?” A REVIEW OF THE GUT MICROBIOME IN OBSESSIVE-COMPULSIVE DISORDER
Turna, J., Kaplan, K. G., Anglin, R., & Ameringen, M. V. (2015) · Depression and Anxiety · doi:10.1002/da.22454 · Cited by 76
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 72
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
Ma, C., & Armstrong, A. W. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.813897 · Cited by 73
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease
Schaefer, M., Sarkar, R., Knop, V., Effenberger, S., Friebe, A., Heinze, L., Spengler, U., Schlaepfer, T. E., Reimer, J., Buggisch, P., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00006 · Cited by 68
Managing Depression during Hepatitis C Treatment
Sockalingam, S., & Abbey, S. E. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400906 · Cited by 60
Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine
McNutt, M. D., Liu, S., Manatunga, A., Royster, E. B., Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Miller, A. H., & Musselman, D. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.330 · Cited by 56
Self-citation
Symptomatic Treatment of Interferon-α–Induced Depression in Hepatitis C
Baraldi, S., Hepgul, N., Mondelli, V., & Pariante, C. M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d9982 · Cited by 54
Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: A Double-Blind, Placebo-Controlled Trial
Morasco, B. J., Loftis, J. M., Indest, D. W., Ruimy, S., Davison, J. W., Felker, B. L., & Hauser, P. (2010) · Psychosomatics · doi:10.1176/appi.psy.51.5.401 · Cited by 53
Neuroinflammation
Mukhara, D., Oh, U., & Neigh, G. N. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00017-5 · Cited by 60
Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Schaefer, M., & Mauss, S. (2008) · Current Drug Abuse Reviews · doi:10.2174/1874473710801020177 · Cited by 48
What does irritable bowel syndrome share with non-alcoholic fatty liver disease?
Scalera, A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i33.5402 · Cited by 48
Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment.
Lucaciu, L., & Dumitrascu, D. L. (2015) · PubMed Central · Cited by 45
Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: An intracranial self-stimulation study
van Heesch, F., Prins, J., Konsman, J. P., Westphal, K. G. C., Olivier, B., Kraneveld, A. D., & Korte, S. M. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.12.013 · Cited by 46
Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis
Sarkar, S., & Schaefer, M. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.06.015 · Cited by 48
Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection
Alvarez‐Uria, G., Day, J., Jafar, A. J. N., Russell, S. K., & Vilar, F. J. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01958.x · Cited by 44
Suicide risk management in research on internet-based interventions for depression: A synthesis of the current state and recommendations for future research
Sander, L., Gerhardinger, K., Bailey, E., Robinson, J., Lin, J., Cuijpers, P. J., & Mühlmann, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.045 · Cited by 44
Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C
Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back‐Madruga, C., Lok, A. S.-F., Stoddard, A. M., & the HALT-C Trial Group (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02106.x · Cited by 43
Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction
Schaefer, M., Sarkar, R., & Díez, C. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit266 · Cited by 42
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis C
de Knegt, R. J., Bezemer, G., Gool, A. R. V., Drenth, J. P. H., Hansen, B. E., Fortuyn, H. A. D., Weegink, C. J., Hengeveld, M. W., & Janssen, H. L. A. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04867.x · Cited by 42
Adaptation of prelimbic cortex mediated by IL-6/STAT3/Acp5 pathway contributes to the comorbidity of neuropathic pain and depression in rats
Zhao, Y.-T., Deng, J. F., Liu, H.-M., Wei, J., Fan, H.-T., Liu, M., Xu, T., Chen, T., He, J., Sun, W., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02503-0 · Cited by 40
Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation
Pinzi, M., Fagiolini, A. M., Koukouna, D., Gualtieri, G., Rescalli, M. B., Pierini, C., Pardossi, S., Patrizio, B., & Cuomo, A. (2025) · Cells · doi:10.3390/cells14191558 · Cited by 47
Can we vaccinate against depression?
Rook, G. A. W., Raison, C. L., & Lowry, C. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.018 · Cited by 39
Self-citation
Can antidepressants prevent interferon-alpha-induced depression? A review of the literature
Almeida, A. G.-D., Guindalini, C., Batista-Neves, S. C., de Oliveira, I. R., Miranda-Scippa, Â. M. D. A., & Quarantini, L. C. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.03.001 · Cited by 39
Psychiatric Care of the Patient With Hepatitis C
Rifai, M. A., Gleason, O. C., & Sabouni, D. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09r00877whi · Cited by 36
Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression
Cassol, E., Misra, V., Morgello, S., Kirk, G. D., Mehta, S. H., & Gabuzda, D. H. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000551 · Cited by 38
Risk factors for the development of depression in patients with hepatitis C taking interferon-α
Smith, K. J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13917 · Cited by 35
Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon-α-induced depression
Su, K. (2015) · Biomedicine · doi:10.7603/s40681-015-0021-x · Cited by 38
Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review and meta-analysis
Ehret, M. J., & Sobieraj, D. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12268 · Cited by 33
Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids
Lotrich, F. E., Sears, B., & McNamara, R. K. (2013) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2013.07.012 · Cited by 32
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin
Waizmann, M., & Ackermann, G. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.02.002 · Cited by 31
Update der S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021/012 Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection
Sarrazin, C., Roß, R. S., Schirmacher, P., Wedemeyer, H. H., Neumann, U. P., Schmidt, H., Spengler, U., Wirth, S., Kessler, H. H., Peck‐Radosavljevic, M., et al. (2010) · Cited by 30
Specific Serotonin Reuptake Inhibitors Prevent Interferon-α–Induced Depression in Patients With Hepatitis C: A Meta-analysis
Jiang, H.-Y., Deng, M., Zhang, Y., Chen, H., Chen, Q., & Ruan, B. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.035 · Cited by 26
What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin
Gara, N., & Ghany, M. G. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit074 · Cited by 25
Factors influencing long‐term changes in mental health after interferon‐alpha treatment of chronic hepatitis C
Schmidt, F., Janssen, G., Martin, G., Lorenz, R., Loeschke, K., Soyka, M., Folwaczny, C., & Schaefer, M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04123.x · Cited by 24
Depression in Late-Life: A Focus on Prevention
Okereke, O. I., Lyness, J. M., Lotrich, F. E., & Reynolds, C. F. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.22 · Cited by 25
Interferon-Induced Psychosis as a "Psychiatric Contraindication" to Hepatitis C Treatment: A Review and Case-Based Discussion
Silverman, B. C., Kim, A. Y., & Freudenreich, O. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70652-6 · Cited by 22
Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C
Almeida, A. G.-D., Quarantini, L. C., Sampaio, A. S., Lyra, A. C., Parise, C. L., Paraná, R., de Oliveira, I. R., Koenen, K. C., Miranda-Scippa, Â. M. D. A., & Guindalini, C. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.06.001 · Cited by 23
Immune System Contributions to the Pathophysiology of Depression
Miller, A. H., & Raison, C. L. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc36 · Cited by 26
Self-citation
Protocolo clínico e diretrizes terapêuticas para hepatite viral C e coinfecções
Virais, A. E. H. (2011) · Cited by 19
Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events
Smith, J. P. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.9.1151 · Cited by 19
Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases
Menon, V., Ransing, R., & Praharaj, S. K. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_18_22 · Cited by 19
Management of common psychiatric conditions in the HIV-positive population
Brogan, K., & Lux, J. Z. (2009) · Current HIV/AIDS Reports · doi:10.1007/s11904-009-0016-x · Cited by 17
Blood Levels of S-100 Calcium-Binding Protein B, High-Sensitivity C-Reactive Protein, and Interleukin-6 for Changes in Depressive Symptom Severity after Coronary Artery Bypass Grafting: Prospective Cohort Nested within a Randomized, Controlled Trial
Pearlman, D. M., Brown, J. R., MacKenzie, T. A., Hernandez, F., & Najjar, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111110 · Cited by 19
Psychiatric Implications of Hepatitis-C Infection
Giunta, B. N., Somboonwit, C., Nikolic, W. V., Rrapo, E., Tan, J. R., Shapshak, P., & Fernandez, F. (2007) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v19.i2-3.20 · Cited by 18
Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications
Hauser, P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i15.1921 · Cited by 18
Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
Ferenci, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.555079 · Cited by 16
Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications
Liu, M., Huang, Y. Y. M., Hsu, S., & Kass, J. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0392-x · Cited by 17
Paroxetine up-regulates neurogenesis in hippocampus-derived neural stem cell from fetal rats
Peng, Z., Xue, F., Wang, H., Zhang, R., Chen, Y.-C., Wang, Y., Zhang, L.-Y., Fan, J., & Tan, Q. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1533-2 · Cited by 16
Psychological and biological mechanisms of cytokine induced depression
Hepgul, N., Mondelli, V., & Pariante, C. M. (2010) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000774 · Cited by 17
Cancer fatigue: a review for psychiatrists
Levy, M. R. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.01.004 · Cited by 15
Can Antidepressants Prevent Pegylated Interferon-α/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?
Hou, X.-J., Xu, J., Wang, J., & Yu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076799 · Cited by 14
Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies
Lotrich, F. E. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121572 · Cited by 12
Management of Psychiatric Disease in Hepatitis C Treatment Candidates
Lotrich, F. E. (2010) · Current Hepatology Reports · doi:10.1007/s11901-010-0035-5 · Cited by 11
Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial
Klein, M. B., Lee, T., Brouillette, M., Sheehan, N. L., Walmsley, S. L., Wong, D., Conway, B., Hull, M., Cooper, C., Haidar, S., et al. (2014) · HIV Clinical Trials · doi:10.1310/hct1504-161 · Cited by 11
Depression and pegylated interferon-based hepatitis C treatment
Papafragkakis, H., Rao, M. S., Moehlen, M., Dhillon, S., & Martin, P. (2012) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s28901 · Cited by 10
Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study
van de Putte, D. E. F., Fischer, K., Posthouwer, D., van Erpecum, K. J., & Mauser‐Bunschoten, E. P. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01940.x · Cited by 11
Pharmacological interventions for prevention of depression in high risk conditions: Systematic review and meta-analysis.
Farooq, S., Singh, S. P., Burke, D. L., Naeem, F., & Ayub, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.024 · Cited by 11
Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study
Hepgul, N., Kodate, N., Anderson, J. E., Henderson, M., Ranjith, G., Hotopf, M. H., & Pariante, C. M. (2012) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2012.07.016 · Cited by 9
Self-citation
When to treat and the benefits of treating hepatitis C in patients with haemophilia
Patel, H., & Heathcote, E. J. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01917.x · Cited by 9
Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk
Lotrich, F. E., Sears, B., & McNamara, R. K. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.10.004 · Cited by 9
Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: A Systematic Review and Meta-Analysis
Al‐Omari, A., Cowan, J., Turner, L., & Cooper, C. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/832689 · Cited by 9
Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy
Sims, O. T., Whalen, C. C., Nackerud, L. G., & Bride, B. E. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a47397 · Cited by 8
Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study
Lin, C. Y., Guu, T., Lai, H., Peng, C., Chiang, J. Y.-J., Chen, H., Li, T., Yang, S.-Y., Su, K., & Chang, J. P. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2019.100035 · Cited by 8
Peginterferon and ribavirin in HCV: Improvement of sustained viral response
Ferenci, P. (2008) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2008.11.001 · Cited by 7
Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C
Stewart, B. J. R., Turnbull, D. A., Mikocka‐Walus, A. A., Harley, H. A. J., & Andrews, J. M. (2013) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-012-9339-7 · Cited by 7
Mental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis C
Martín-Subero, M., & Díez, C. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.041 · Cited by 7

Authors: RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., & MILLER, A. H.
Affiliations: Emory University (US)
University of Pennsylvania (US)
Rush University Medical Center (US)
Kaiser Permanente (US)
Albert Einstein College of Medicine (US)
Corresponding author: MILLER, A. H.
ORCID: RAISON, C. L.
WOOLWINE, B. J.
BORISOV, A. S.
STAAB, J. P.
ZAJECKA, J. M.
REINUS, J. F.
MILLER, A. H.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2007-03-20
Volume: 25
Issue: 10
Pages: 1163-1174
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1111/j.1365-2036.2007.03316.x
OpenAlex: W1482765914
Cited by: 142
References: 60
Citations by year: 2025: 1 · 2024: 1 · 2022: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 23 · 2012: 17
FWCI: 10.96
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
Pfizer
National Institutes of Health
National Institute of Mental Health (MH-00680, K23MH064619, MH 60723, MH 64619, R01MH060723, MH060723)
National Center for Research Resources (M01-RR00039, M01RR000039)
NIH Clinical Center
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: paroxetine, antidepressant prophylaxis, depression prevention, interferon-alpha, ribavirin, hepatitis C, depressive symptoms, antiviral therapy adverse effects, Montgomery-Asberg Depression Rating Scale
MeSH terms: Adolescent, Adult, Aged, Antiviral Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Ribavirin, Interferon-alpha, Paroxetine, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks